CEO Shawn Leland (Elevation)

El­e­va­tion On­col­o­gy bags $65M to push failed Mer­ri­mack drug through PhII

Shawn Le­land hadn’t even heard of NRG1 as an on­col­o­gy tar­get un­til he was sit­ting in a pre­sen­ta­tion at ES­MO 2018 in Mu­nich. Alex Drilon, an on­col­o­gist at the Memo­r­i­al Sloan Ket­ter­ing Can­cer Cen­ter in New York, was pre­sent­ing on tar­get­ed ther­a­pies for lung can­cer — and Le­land was en­thralled.

“He put up one slide with­in that pre­sen­ta­tion that de­scribed the tar­get of NRG1 gene fu­sion and the fact that they were po­ten­tial­ly drug­gable with a HER3 mon­o­clon­al an­ti­body ap­proach,” Le­land said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.